argenx NV ADR (ARGX)
argenx NV ADR (ARGX) carries a ŷRobot AI score of 89 out of 100. The model's fair value estimate is $921.36, 12.6% above the last close of $818.30. The chart signal reads Bullish.
| Metric | ARGX |
|---|---|
| AI score | 89 / 100 |
| Chart signal | Bullish |
| Fair value estimate | $921.36 |
| Upside to fair value | 12.6% |
| Previous close | $818.30 |
| P/E | 36.49 |
| Price / sales | 10.95 |
| Market cap | $51.88B |
| EPS | 26.28 |
| Revenue growth | 61.1% |
| 1-year price change | 22.0% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about ARGX
Is ARGX overvalued or undervalued right now?
As of Oct 14, 2026, ŷRobot's fair-value model estimates argenx NV ADR (ARGX) at $921.36 against a last close of $818.30, implying 12.6% upside to the model's estimate.
Is ARGX's chart signal bullish or bearish?
The chart-signal model classifies ARGX as Bullish as of Oct 14, 2026, with a signal score of 0.16 on a -1 to 1 scale.
What is ARGX's ŷRobot AI score?
ARGX scores 89 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 14, 2026.
Is ARGX stock expensive on P/E and P/S?
ARGX trades at 36.5 times earnings and 11.0 times sales as of Oct 14, 2026.
What does ARGX's seasonal forecast show?
ŷRobot's seasonal forecast curve for ARGX reads +4.8% at 30 days, +17.8% at 90 days, and +22.0% at one year as of Oct 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is ARGX growing?
argenx NV ADR's revenue growth is +61.1% and free-cash-flow growth is +6.0% on the latest reported figures.
ARGX chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.